FR-901228 Fujisawa/National Cancer Institute
Vigushin, D.M.
Current Opinion in Investigational Drugs 3(9): 1396-1402
2002
ISSN/ISBN: 1472-4472 PMID: 12498018 Document Number: 542915
The depsipeptide FR-901228 is a histone deacetylas inhibitor under development by Fujisawa and the National Cancer Institute as a potential treatment for neoplasm. By May 2002, phase II trials had commenced in the US [452248], [461017].
Document emailed within 1 workday
Related Documents
Hoyt, D.B.; Holcomb, J.; Abraham, E.; Atkins, J.; Sopko, G. 2004: Working Group on Trauma Research Program summary report: National Heart Lung Blood Institute (NHLBI), National Institute of General Medical Sciences (NIGMS), and National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), and the Department of Defense (DOD) Journal of trauma 57(2): 410-415Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Raju, T.N.K.; Nelson, K.B.; Ferriero, D.; Lynch, J.Kylan. 2007: Ischemic perinatal stroke: summary of a workshop sponsored by the National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke Pediatrics 120(3): 609-616
Chiarodo, A. 1991: National Cancer Institute roundtable on prostate cancer: future research directions Cancer Research 51(9): 2498-2505
Ornellas, A.A.; Khouri, F.R.; Campos, F.; Koifman, N.; Quirino, R. 1999: Cancer of the urethra in women: experience of the National Institute of Cancer of Brazil: 1992-1997 Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 9(2): 292-298
Zwiebel, J. 2016: The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program Clinical Advances in Hematology and Oncology: H&o 14(3): 157-159
Talukder, M.H.; Jabeen, S.; Shaheen, S.; Islam, M.J.; Haque, M. 2007: Pattern of cancer in young adults at National Institute of Cancer Research and Hospital (NICRH), Bangladesh Mymensingh medical journal: MMJ 16(2 Suppl): S28-S33
Goldin, A.; Venditti, J.M.; Carter, S.K. 1977: Screening at the National Cancer Institute National Cancer Institute Monograph 1977(45): 37-48
Schepartz, S.A. 1985: The National Cancer Institute's Drug Development Program Progress in Clinical and Biological Research 197: 73-82
Sattin, R W.; Rubin, G L.; Wingo, P A.; Webster, L A.; Ory, H W. 1987: Oral-Contraceptive Use and the Risk of Breast Cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development Obstetric and Gynecologic Survey 42(2): 120-121
Symmans, W.Fraser. 2014: Translational research in the National Cancer Institute's cooperative groups Clinical Advances in Hematology and Oncology: H&o 12(11): 785-787
Link, D. 1995: New NCI director confronts troubled agency. National Cancer Institute Gmhc Treatment Issues: the Gay Men's Health Crisis Newsletter of Experimental Aids Therapies 9(10): 9
1987: Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development JAMA 257(6): 796-800
Chabner, B.A.; Curt, G.A.; Hubbard, S.M. 1984: Surgical oncology research development: the perspective of the National Cancer Institute Cancer Treatment Reports 68(6): 825-829
Ivy, S.Percy.; Ivy, S.Percy. 2015: The National Cancer Institute's Experimental Therapeutics Clinical Trials Network Clinical Advances in Hematology and Oncology: H&o 13(3): 144-146
Pérez Montiel, D.; Puebla Mora, A.Graciela.; Cantú de León, D. 2004: Vulvar metastatic disease: experience at the National Institute of Cancer of Mexico Ginecologia y obstetricia de Mexico 72: 215-218
Kaba, H.; Fukuda, H.; Yamamoto, S.; Ohashi, Y. 2004: Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(8): 1187-1192
Evans, W.K.; Coyle, D.; Gafni, A.; Walker, H. 2003: Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis Chronic diseases in Canada 24(4): 102-107
Lachgar, A.; Sahli, N.; Toulba, A.; Kebdani, T.; Benjaafar, N. 2015: Lung cancer: treatment pathway in the radiotherapy department at the National Oncology Institute of Rabat Pan African medical journal 21: 253
Cognetti, G.; Paradiso, B.; Truccolo, I.; Ugolini, D.; Santi, L. 1995: Information oncologic tools produced by the U.S. National Cancer Institute: how much are they known and used? Results of an enquiry in Italy Tumori 81(5): 347-350